Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer’s Disease

Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease

(2010) Gary Small et al.   Alzheimers & Dementia

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

Rivastigmine in the Treatment of Dementia Associated with Parkinson’s Disease: Effects on Activities of Daily Living

(2010) Jason T. Olin et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Prediction of Institutionalisation in Dementia

(2009) Melanie Luppa et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Impact of Rivastigmine on Caregiver Burden Associated with Alzheimer’s Disease in Both Informal Care and Nursing Home Settings

(2009) George T Grossberg   DRUGS & AGING

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review

(2009) A. Kurz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Predicting time to nursing home placement based on activities of daily living scores – a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil

(2009) Hind T Hatoum et al.   JOURNAL OF MEDICAL ECONOMICS

Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations

(2008) Martin R. Farlow et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS